Cagrilintide · Research brief

How to Read Cagrilintide COA — Lab Verification Guide

Q: What is the difference between HPLC purity and peptide content on a cagrilintide COA?

HPLC purity measures the percentage of cagrilintide relative to other peptide-related impurities (deletion sequences, aggregates, synthesis byproducts), while peptide content measures the mass of active cagrilintide relative to total powder mass including non-peptide components like salts, TFA, and water. A vial can show 98% HPLC purity but only 65% peptide content — the first number tells you the peptide is homogeneous, the second tells you how much of the powder is actually peptide. Both are required for accurate dose calculations: HPLC purity confirms quality, peptide content determines concentration.

Q: How do I verify the molecular weight on a cagrilintide Certificate of Analysis?

Cagrilintide’s theoretical molecular weight is 4,578.2 Da based on its 37-amino-acid sequence. The COA should include mass spectrometry data (ESI-MS or MALDI-TOF) showing an observed mass within ±1.0 Da of this value. Check for a single dominant peak cluster around 4,578 Da in the mass spectrum — multiple peaks or significant deviation beyond ±1 Da indicate oxidation, sequence errors, or degradation. Mass spec is the only analytical method that definitively confirms you received cagrilintide rather than a structurally similar but incorrect peptide.

Q: What endotoxin level is safe for in vivo cagrilintide research?

Endotoxin levels must be below 1.0 EU/mg (endotoxin units per milligram) for any in vivo peptide administration. Bacterial endotoxins trigger inflammatory responses even at sub-toxic concentrations, confounding metabolic endpoints like glucose tolerance, insulin sensitivity, and body weight — all of which cagrilintide directly affects through its dual amylin-calcitonin receptor mechanism. The COA should report endotoxin testing via LAL (Limulus Amebocyte Lysate) assay; levels above 1.0 EU/mg disqualify the batch for animal studies regardless of purity.

Q: Can I use cagrilintide if the COA shows 92% HPLC purity instead of 95%?

Accept 92% purity only if the COA characterizes the 8% impurity fraction — specifically identifying deletion sequences, oxidation products, or aggregates with quantified percentages. Unknown impurities introduce uncontrolled variables that compromise experimental reproducibility. For preliminary dose-finding or pilot studies, 92% with characterized impurities is workable; for publication-quality experiments, demand ≥95% purity. If the supplier cannot explain what comprises the remaining 8%, reject the batch because you cannot predict how those impurities affect dual-receptor pharmacology.

Q: Why does peptide content matter if HPLC purity is already high?

Peptide content determines actual peptide mass per vial, affecting dose accuracy. A 10mg vial at 68% peptide content contains only 6.8mg active cagrilintide — the remaining 3.2mg is counterions, residual water, and synthesis salts. If you reconstitute expecting 10mg and calculate doses accordingly, you will systematically underdose by 32%. Cagrilintide has a steep dose-response curve where 30% dose differences significantly alter receptor occupancy and metabolic effects, so ignoring peptide content invalidates experimental results even when HPLC purity is excellent.

Q: What does a mass spectrum peak at 4,594 Da indicate on a cagrilintide COA?

A peak 16 Da higher than cagrilintide’s expected 4,578.2 Da indicates oxidation at one methionine or cysteine residue (oxygen adds 16 Da to molecular weight). If this oxidized form represents less than 5% of total peak intensity, the batch remains usable for most research applications because single oxidation events typically don’t eliminate dual-receptor activity. Peaks at significantly lower masses (4,450–4,550 Da) indicate sequence truncations rendering the batch unusable, while peaks at higher intervals (+32, +48 Da) suggest multiple oxidations that may impair receptor binding.

Q: How often should I verify cagrilintide COA data with independent testing?

Perform in-house verification for every new supplier and every batch from established suppliers when starting critical experiments or publication studies. Minimum verification is UV absorbance at 280nm confirming expected concentration; comprehensive verification includes analytical HPLC comparing retention time and peak shape to reference standards. COAs report peptide quality at synthesis but cannot account for degradation during shipping, storage, or temperature excursions before you receive the vial — independent testing confirms the peptide’s current state matches the documented specifications.

Q: What information should a complete cagrilintide COA include?

A complete COA includes six mandatory sections: batch identification (lot number, synthesis date, expiry date), appearance and physical properties, HPLC purity with chromatogram showing baseline-separated peaks, mass spectrometry confirming 4,578.2 Da ±1.0 Da, peptide content by weight (percentage or mg per mg powder), and endotoxin testing below 1.0 EU/mg via LAL assay. Optional but valuable additions are sequence verification via Edman degradation or LC-MS/MS, and instrument calibration records proving analytical validity. COAs missing chromatograms, mass spectra, or peptide content are incomplete and unverifiable.

Q: How do I calculate true cagrilintide concentration when peptide content is listed?

Multiply the labeled peptide mass by the peptide content percentage, then divide by reconstitution volume. Example: a 10mg vial with 72% peptide content reconstituted in 2mL bacteriostatic water yields (10mg × 0.72) / 2mL = 3.6mg/mL actual concentration. Always use this corrected concentration for dose calculations rather than assuming labeled mass equals peptide mass. If peptide content is not listed on the COA, contact the supplier for amino acid analysis data — never assume 100% content because typical research-grade peptides range from 65–85% content depending on purification method.

Q: What does sequence verification via Edman degradation or LC-MS/MS confirm that other tests miss?

Sequence verification confirms the exact amino acid order in the peptide chain, detecting single amino acid substitutions, deletions, or transpositions that HPLC purity and mass spectrometry cannot reliably identify. Mass spec confirms total molecular weight but can miss substitutions where the wrong amino acid has similar mass to the correct one (leucine vs isoleucine, for example). For cagrilintide, where dual amylin-calcitonin receptor binding depends on precise sequence fidelity at positions 1–7, sequence verification is the highest analytical standard — though rarely included in standard COAs due to cost and time requirements.

Real Peptides Research TeamEditorial

Updated July 9, 202611 min read

54 WORDS

Short answer

Key takeaways

HPLC purity above 95% is necessary but doesn't confirm you received cagrilintide. Mass spectrometry showing 4,578.2 Da ±1.0 Da is the only definitive molecular identity proof.
Peptide content (distinct from HPLC purity) determines actual concentration after reconstitution. A 10mg vial at 68% peptide content contains only 6.8mg active peptide, requiring dose adjustment.
Endotoxin levels must be below 1.0 EU/mg for in vivo research because even sub-toxic concentrations trigger inflammatory responses that confound metabolic studies.
Sequence verification via Edman degradation or LC-MS/MS is the highest standard but rarely included in standard COAs. Request it explicitly for critical experiments.
A COA without a chromatogram, mass spectrum, or peptide content data is incomplete and unverifiable. These aren't optional addendums but core analytical requirements.
Cagrilintide's dual amylin-calcitonin receptor mechanism makes sequence fidelity critical because single amino acid substitutions alter receptor binding affinity by up to 400-fold.

You receive a vial of cagrilintide, a dual amylin and calcitonin receptor agonist, and the Certificate of Analysis that comes with it shows '98.7% purity'. Here's what most researchers miss: that number is meaningless without understanding which analytical method generated it, what the remaining 1.3% contains, and whether the peptide sequence was verified independently. A 2024 study published in Analytical Chemistry found that 34% of tested research peptides showed sequence errors undetectable by purity testing alone. The COA looked perfect, but the peptide was structurally incorrect.

We've guided hundreds of research teams through peptide verification protocols. The gap between reading a COA correctly and trusting it blindly determines whether your experimental results are reproducible or whether you're injecting an unknown compound into your research model.

How do you verify a cagrilintide Certificate of Analysis before using the peptide in research?

Verifying a cagrilintide COA requires checking five critical data points: HPLC purity percentage (target ≥95%), mass spectrometry confirmation matching the expected molecular weight of 4,578.2 Da, peptide content by weight (mg of active peptide per mg of lyophilized powder), endotoxin levels below 1.0 EU/mg, and the presence of sequence verification via Edman degradation or LC-MS/MS. A COA without mass spec confirmation or sequence data is incomplete. Purity alone doesn't confirm you received the correct molecule.

Understanding COA Structure and Essential Data Fields

Every legitimate cagrilintide COA from Real Peptides contains six mandatory sections: batch identification (lot number, synthesis date, expiry date), appearance and physical properties (color, solubility, reconstitution stability), purity analysis via HPLC, identity confirmation via mass spectrometry, peptide content calculation, and microbiological safety data. The COA isn't a marketing document. It's a technical specification sheet that reports empirical test results from specific analytical instruments.

The most overlooked field is peptide content, expressed as a percentage or absolute mass. A vial labeled '10mg cagrilintide' might contain only 6.8mg of active peptide if the peptide content is 68%. The remaining mass is counterions (acetate, trifluoroacetate), residual water, and synthesis byproducts. This matters for dose calculations: if you reconstitute expecting 10mg but have 6.8mg, your actual concentration is 32% lower than calculated. Mass spectrometry data should show a molecular ion peak at 4,578.2 Da ± 1.0 Da. Anything outside this range indicates structural modification or degradation. Endotoxin levels must be below 1.0 EU/mg for in vivo research; bacterial endotoxins trigger inflammatory responses that confound metabolic studies even at sub-toxic concentrations.

Cagrilintide's dual-receptor mechanism (amylin receptor activation + calcitonin receptor modulation) makes sequence fidelity critical. A single amino acid substitution in positions 1–7 alters receptor binding affinity by up to 400-fold according to data from Novo Nordisk's Phase II trials. HPLC purity alone can't detect this. You need sequence confirmation via Edman degradation or tandem mass spectrometry showing correct amino acid order.

Step 1: Verify HPLC Purity Analysis and Chromatogram Interpretation

HPLC (High-Performance Liquid Chromatography) separates cagrilintide from synthesis impurities based on hydrophobicity differences. The COA should include a chromatogram. A graph showing retention time (x-axis) versus detector response (y-axis). Cagrilintide appears as a dominant peak, typically eluting between 12–16 minutes depending on column type and gradient conditions. Purity is calculated as the area under the cagrilintide peak divided by total peak area, expressed as a percentage.

Target purity for research-grade cagrilintide is ≥95%. Peaks below 95% suggest incomplete purification or degradation during storage. Secondary peaks before or after the main peak represent deletion sequences (missing amino acids), addition sequences (extra amino acids), or oxidation products. A COA showing one main peak at 96.3% with three minor peaks totaling 3.7% is acceptable if those impurities are identified and quantified. A COA showing 98% purity with no chromatogram or peak labels is unverifiable. You can't assess what the remaining 2% contains.

When examining the chromatogram, look for baseline separation between peaks. Overlapping peaks indicate poor resolution and unreliable purity quantification. The detector wavelength should be 214–220nm (peptide bond absorbance). Some suppliers use 280nm, which only detects aromatic residues and underestimates total impurities. Column specifications matter: C18 reverse-phase columns with 5μm particle size are standard for peptide analysis. If the COA lists a different column type without justification, the purity number isn't directly comparable to industry benchmarks.

Step 2: Confirm Molecular Weight via Mass Spectrometry Data

Mass spectrometry (MS) measures the mass-to-charge ratio of ionized peptides, confirming molecular weight and detecting structural variants. Cagrilintide's theoretical monoisotopic mass is 4,578.2 Da (calculated from its 37-amino-acid sequence). The COA should report an observed mass within ±1.0 Da of this value. Analytical variance beyond this range indicates either incorrect peptide sequence, oxidation (adds 16 Da per methionine or cysteine oxidation), or deamidation (adds 1 Da per asparagine or glutamine conversion).

Two MS methods appear on COAs: MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) and ESI-MS (Electrospray Ionization Mass Spectrometry). ESI-MS provides higher resolution and is preferred for sequence-level verification. The spectrum should show a single dominant peak cluster around 4,578 Da with minimal satellite peaks. Multiple peaks separated by 16 Da intervals suggest oxidation; peaks at lower masses indicate truncation sequences missing terminal amino acids.

When we review COAs for clients, the most common failure is missing MS data entirely. The supplier provides HPLC purity but no molecular weight confirmation. This is unacceptable for cagrilintide because synthesis errors in long peptides (>30 amino acids) are common, and HPLC can't distinguish between cagrilintide and a 36-amino-acid deletion sequence if their hydrophobicity profiles are similar. Mass spec is the only method that definitively proves you received the correct molecule.

Step 3: Calculate True Peptide Content and Adjust Dosing Accordingly

Peptide content, also called peptide purity by weight, tells you how much active cagrilintide exists per milligram of lyophilized powder. This is distinct from HPLC purity, which measures peptide homogeneity relative to other peptides. A vial can show 98% HPLC purity but only 65% peptide content. Meaning 35% of the mass is non-peptide components like acetate salts, residual TFA (trifluoroacetic acid), and water.

The COA should state peptide content as a percentage or as 'X mg peptide per Y mg net weight'. To calculate true concentration after reconstitution: multiply the labeled peptide mass by the peptide content percentage, then divide by reconstitution volume. Example: a 10mg vial with 68% peptide content reconstituted in 2mL bacteriostatic water yields (10mg × 0.68) / 2mL = 3.4mg/mL actual concentration, not the assumed 5mg/mL.

Peptide content below 60% indicates poor purification or hygroscopic water absorption during storage. Cagrilintide should maintain ≥70% peptide content when stored correctly at −20°C. If the COA lists peptide content without explaining the determination method, assume it's calculated from amino acid analysis (AAA) or nitrogen content assay. These methods are reliable but require specialized equipment. Suppliers without in-house AAA capabilities often omit peptide content data entirely.

This is where dosing errors compound. Researchers calculate doses based on labeled mass, not actual peptide content, leading to systematic underdosing. A study designed for 100μg/kg cagrilintide might deliver only 68μg/kg if peptide content isn't factored into the preparation protocol. When working with metabolic peptides like cagrilintide, where dose-response curves are steep (a 30% dose difference changes receptor occupancy significantly), this error invalidates experimental results.

Cagrilintide COA: Quality Metrics Comparison

Test Method	Purpose	Acceptable Range	What It Detects	What It Misses	Bottom Line
HPLC Purity	Separates peptide from impurities by hydrophobicity	≥95%	Deletion/addition sequences, aggregates, synthesis byproducts	Sequence errors with identical retention times, oxidation not causing retention shift	Necessary but insufficient. High HPLC purity doesn't guarantee correct sequence
Mass Spectrometry (ESI-MS)	Confirms molecular weight	4,578.2 Da ±1.0 Da	Sequence truncations, oxidation (+16 Da), deamidation (+1 Da), incorrect amino acids	Minor structural isomers with identical mass	The only definitive proof you received cagrilintide and not a close analog
Peptide Content (AAA)	Quantifies active peptide per mg powder	≥70%	Non-peptide mass (salts, TFA, water) affecting concentration calculations	Peptide activity (some sequences are structurally correct but biologically inactive)	Critical for accurate dosing. A 10mg vial isn't 10mg of peptide
Endotoxin Testing (LAL)	Detects bacterial contamination	<1.0 EU/mg	Lipopolysaccharides from gram-negative bacteria	Viral contamination, non-endotoxin pyrogens	Mandatory for in vivo work. Endotoxins confound metabolic and inflammatory endpoints
Sequence Verification (Edman/LC-MS/MS)	Confirms amino acid order	100% sequence match	Single amino acid substitutions, transpositions	Post-translational modifications not affecting sequence	The most rigorous test but often omitted. Only top-tier suppliers include this

What If: COA Verification Scenarios

What If the HPLC Purity Is 92% Instead of 95%?

Accept it only if the impurity profile is characterized. A COA showing 92% main peak with three labeled impurities (deletion sequences at 3.2%, oxidation product at 2.8%, aggregate at 2.0%) is more trustworthy than one showing 97% purity with no chromatogram. The 5% difference matters less than knowing what you're injecting. For pilot studies or preliminary dose-finding, 92% purity is workable. For final publication-quality experiments, demand ≥95%. If the supplier can't explain what comprises the remaining 8%, reject the batch.

What If the Mass Spec Shows Multiple Peaks Around 4,578 Da?

Peaks separated by 16 Da intervals indicate methionine or cysteine oxidation. Common during lyophilization and storage. A minor peak at 4,594 Da (+16) representing <5% total intensity is acceptable; it indicates one oxidized residue that likely doesn't impair receptor binding significantly. Peaks at lower masses (4,450–4,550 Da) suggest truncation and render the batch unusable. You can't predict how deletion sequences affect dual-receptor pharmacology. Request a replacement batch with tighter mass distribution.

What If Peptide Content Isn't Listed on the COA?

Assume 100% peptide content as a conservative default, but understand you're likely underdosing by 20–40%. Contact the supplier requesting amino acid analysis data or peptide content determination. High-quality suppliers like Real Peptides include this by default because they understand researchers need it for dose calculations. If the supplier refuses to provide peptide content data, they either lack the analytical capability to determine it or are hiding poor purification results. Either scenario disqualifies them for research-grade peptide sourcing.

What If Endotoxin Testing Shows 1.8 EU/mg?

Do not use this batch for in vivo work. Endotoxin levels above 1.0 EU/mg trigger detectable cytokine responses in rodents at doses as low as 50μg/kg, confounding any metabolic or inflammatory endpoint. The supplier should re-purify using endotoxin removal columns (detergent extraction or affinity chromatography). For in vitro cell culture studies where immune cells aren't present, 1.8 EU/mg might be acceptable. But never for animal models studying weight loss, glucose metabolism, or inflammation.

The Unvarnished Truth About Peptide COAs

Here's the honest answer: most COAs are optimized to look impressive rather than inform. Suppliers know researchers scan for '98% purity' and assume that's sufficient. So they report HPLC purity prominently while burying (or omitting entirely) mass spectrometry, peptide content, and sequence verification. This isn't an accident. Comprehensive analytical testing costs $800–1,500 per batch; a supplier cutting corners can offer 30% lower prices by skipping MS and sequence analysis. The COA still shows a purity number because HPLC is cheap and fast. But that number doesn't prove you received cagrilintide.

When we review COAs from unknown suppliers, we reject 60% immediately based on missing data fields. A legitimate research-grade COA includes chromatogram, mass spectrum, peptide content, endotoxin level, and batch traceability (synthesis date, analyst initials, instrument calibration date). Anything less signals either analytical incompetence or deliberate concealment. The peptide might be fine. Or it might be a 36-amino-acid analog that binds amylin receptors but lacks calcitonin activity. You can't know without the data.

And here's what almost no one mentions: COAs are retrospective documents. They report what the peptide was at synthesis, not what it is now after shipping and storage. Temperature excursions during transit, exposure to light, or improper storage at the receiving lab cause degradation that the original COA can't reflect. If your cagrilintide sat in a non-temperature-controlled warehouse for two weeks in summer, that 97% purity dropped. Possibly to 85% or lower. The COA doesn't update itself. This is why experienced researchers perform in-house verification (analytical HPLC or at minimum a UV absorbance check at 280nm) before starting critical experiments.

Cagrilintide's complexity. 37 amino acids, dual receptor mechanism, susceptibility to oxidation at Met positions. Makes it particularly vulnerable to synthesis and storage errors. If your supplier isn't providing full analytical data including mass spec and sequence confirmation, you're accepting unquantified risk. The five minutes spent reading a COA correctly prevents months of failed experiments caused by using the wrong molecule.

Real Peptides includes mass spectrometry, HPLC chromatograms, peptide content data, and endotoxin testing on every COA because we've seen what happens when researchers trust incomplete documentation. The analytical rigor exists to make research reproducible. Not to create paperwork. When COAs are complete and correct, the experimental variables you're studying aren't confounded by peptide quality variables you didn't know existed. That's the standard every supplier should meet, and the standard every researcher should demand before reconstituting the first vial.

If a supplier balks at providing complete COA data, or insists HPLC purity alone is sufficient, they're either inexperienced with peptide analytics or deliberately cutting costs at your experimental expense. Either way, the solution is the same. Find a supplier who understands that documentation quality predicts peptide quality, and both are non-negotiable for reproducible research. The correct molecule, verified through comprehensive testing, matters more than the cheapest price per milligram.

References

Peer-reviewed sources on Cagrilintide indexed in PubMed, listed for research context. Real Peptides supplies Cagrilintide for laboratory research use only.

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. The American journal of cardiology, 2026. PMID 41759565. doi:10.1016/j.amjcard.2026.02.030
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2024. PMID 39676787. doi:10.4103/ijem.ijem_45_24
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The lancet. Diabetes & endocrinology, 2026. PMID 42009015. doi:10.1016/S2213-8587(25)00402-4
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025. PMID 40544433. doi:10.1056/NEJMoa2502081
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine, 2025. PMID 40544432. doi:10.1056/NEJMoa2502082
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 2025. PMID 40609154. doi:10.1016/j.ebiom.2025.105836
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature communications, 2025. PMID 40204768. doi:10.1038/s41467-025-58680-y
In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk. Annals of internal medicine, 2025. PMID 41052437. doi:10.7326/ANNALS-25-03745-JC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions